Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

Kurt A. Jaeckle, S. K. Anderson, Erin L. Twohy, Jesse G. Dixon, Caterina Giannini, Robert Brian Jenkins, Merrill J. Egorin, Jann N Sarkaria, Paul D. Brown, P. J. Flynn, John Schwerkoske, Jan Craig Buckner, Evanthia Galanis

Research output: Contribution to journalComment/debate

Abstract

The last author's first name was truncated in the initial online publication. The original article has been corrected.

Original languageEnglish (US)
Number of pages1
JournalJournal of neuro-oncology
Volume143
Issue number3
DOIs
StatePublished - Jul 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this